Avista will apply its single-cell adeno-associated virus (AAV) engineering scAAVengr platform to advance intravitreal AAV capsids, which match capsid profiles defined by Roche. The deal, of which Avista Therapeutics will receive an upfront payment of $7.5 million and potentially receive further payments that exceed $1 billion if certain milestones are met, aims to co-develop AAV vectors for use in gene therapies that can treat eye diseases. “Under the terms of the agreement, Avista will be responsible for the design, screening…